Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2025-12-25 @ 4:04 AM
NCT ID:
NCT02828202
Eligibility Criteria:
1. Cohort Patients with Resectable stage II or III
Inclusion Criteria:
Patients diagnosed with resectable stage IIA/IIB/IIC or III melanoma, confirmed by histological exam.
Naïve of systemic treatment for resectable stage II or III. Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria).
Aged ≥ 18 years. Consenting to participate (signed informed consent).
Exclusion Criteria:
Patients refusal. Choroid melanoma. Resectable stage 1 melanoma. Stage 4, unresectable primitive or unresectable stage 3 melanoma. Patients under guardianship and under trusteeship.
2. Cohort patients with Unresectable stage III or stage IV (resectable or not) or unresectable primary:
Inclusion Criteria:
Patients diagnosed with an advanced melanoma, confirmed by histological exam. Unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma ; or patients treated by neoadjuvant treatment (exceptional) Naïve of systemic treatment for unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma, except adjuvant treatment.
Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria).
Aged ≥ 18 years. Consenting to participate (signed informed consent).
Exclusion Criteria:
Resectable stage 1, 2 or 3 melanoma. Patients refusal. Choroid melanoma. Patients under guardianship and under trusteeship.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02828202
Study Brief:
Protocol Section:
NCT02828202